CHADDS FORD, Pa., Oct. 8 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its third quarter financial results on October 29, 2009 and will host a conference call and webcast at 9:00 a.m. ET that day to discuss these results.
David P. Holveck, president and chief executive officer, Ivan Gergel, M.D., executive vice president of research and development, Alan Levin, chief financial officer and Blaine Davis, vice president, corporate affairs will host the call.
Investors and other interested parties may call 800-798-2884 (domestic) or 617-614-6207 (international) and enter passcode 12555118. Please dial in 10 minutes prior to the scheduled start time.
A replay of the call will be available from October 29 at 12:00 p.m. ET until 12:00 a.m. ET on November 4 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 66458151.
A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 a.m. ET on November 4. The replay can be accessed by clicking on "Upcoming Events" in the Investor Relations section of the website.
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM®, a topical patch to relieve the pain of postherpetic neuralgia; Percocet® and Percodan® tablets for the relief of moderate-to-moderately severe pain; FROVA® tablets for the acute treatment of migraine attacks with or
|SOURCE Endo Pharmaceuticals|
Copyright©2009 PR Newswire.
All rights reserved